By Iain Gilbert
Date: Tuesday 07 Oct 2025
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that Baxdrostat had met its primary endpoint in the Bax24 Phase III trial, delivering a "statistically significant and clinically meaningful reduction" in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension.
AstraZeneca said the drug was tested at a two-milligram dose alongside...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news